Find a study
Browse recruiting studies near you — free to check, always your choice.
223 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- DepressionAnxiety
Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
Testing whether therapy sessions can help teens and young adults with sickle cell cope with
📍 Children's Hospital Los Angeles · Los Angeles, CA · Get directions →
The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black adolescents and young adults in coping with race related stress. The study will consist of a small, purposeful, non-randomized sample (N = 30) of clients enrolled into a 10-session Acceptance and Commitment Therapy group.
- Depression
Inflammation and Depression in People With HIV
Testing whether inflammation affects brain circuits linked to depression symptoms in people with HIV
📍 Grady Memorial Hospital · Atlanta, GA · +1 more US site · Get directions →
The purpose of this 10-week, double-blind, placebo-controlled study is to determine whether inflammation impacts reward and motor neural circuitry to contribute to depressive symptoms like anhedonia and psychomotor slowing in people with Human Immunodeficiency Virus (HIV) and depression. Sixty male and female patients with HIV who have depression, anhedonia and high inflammation and are stable on effective treatment for their HIV will be randomized to receive either the anti-inflammatory drug baricitinib or a placebo for 10 weeks.
- Depression
The Role of mGluR5 in CBT-I
Testing how a brain receptor may affect CBT-I for insomnia in people with depression
📍 Stony Brook University: Dept of Psychiatry · Stony Brook, NY · Get directions →
This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.
- Depression
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
Testing brain scan and EEG measures to predict response to depression treatment
📍 Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 · Austin, TX · Get directions →
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.
- Depression
5-HTP and Creatine for Depression R33 Phase
Testing whether 5-HTP and creatine added to treatment helps depression
📍 University of Utah Department of Psychiatry · Salt Lake City, UT · Get directions →
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 weeks.
- Dementia / Alzheimer'sParkinson's disease
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
Testing whether a tributyrin supplement helps memory, thinking, and balance in adults with Parkinson
📍 Domino's Farms · Ann Arbor, MI · Get directions →
The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation.
- Parkinson's disease
Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms
Testing a non-invasive brain stimulation device to improve Parkinson’s movement problems
📍 U LLC Headquarters · Cleveland, OH · Get directions →
This study tests a new, non-invasive brain stimulation device called Sphere V3.0 to help improve movement problems in people with Parkinson's disease. The device delivers gentle electrical signals to the scalp using small electrodes placed on the head.
- Depression
Intravenous Ketamine for Treatment-Resistant Depression
Testing how a 40-minute IV ketamine infusion affects brain and mood in adults with hard-to-treat
📍 Mayo Clinic in Rochester · Rochester, MN · Get directions →
The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA and Glu levels from baseline to 24-hr postinfusion utilizing LCMS, with baseline to 24-hr post-infusion change in depression (MADRS) in 30 TRD adults.
- Fatty liver disease (NASH/MASH)
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
Testing an experimental medicine for MASLD or MASH in adults
📍 Arizona Liver Health · Chandler, AZ · +1 more US site · Get directions →
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B).
- Depression
Study of ALTO-300 in MDD
Testing whether ALTO-300 works better than placebo for depression
📍 Site 200 · Phoenix, AZ · +39 more US sites · Get directions →
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
- DepressionAnxiety
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
Testing personalized brain stimulation for ongoing concussion symptoms
📍 UCLA · Westwood, Los Angeles, CA · Get directions →
The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury.
- Parkinson's disease
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
Testing whether a low-dose seizure medicine can help Parkinson’s psychosis
📍 Johns Hopkins · Baltimore, MD · Get directions →
This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks.
- Depression
Ketamine Alcohol (in Treatment-Resistant Depression)
Testing ketamine infusions for depression in people who also have alcohol use risk
📍 University of Iowa Health Care · Iowa City, IA · Get directions →
A single subanesthetic dose infusion of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and robust antidepressant effects in patients with treatment-refractory major depressive disorder (TRD). A family history of an alcohol use disorder (Family History Positive, FHP) is one of the strongest identified predictors of an improved antidepressant response to ketamine.
- Depression
Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures
Testing how feasible it is to prescribe antidepressants after fragility fractures in adults 50 and
📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →
The goal of this pilot study is to learn about the feasibility about prescribing anti-depressants at discharge in patients aged 50 years and older with a lower extremity fragility fracture. The main questions it aims to answer are: * What are the obstacles to enrolling patients and prescribing anti-depressants among older adults?
- Multiple sclerosis (MS)
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
Testing the safety and effects on disease and immune cells of one dose of YTB323 in people with
📍 Novartis Investigative Site · Darlinghurst, New South Wales · Get directions →
This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.
- Parkinson's disease
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Testing a treatment in people with early Parkinson’s disease who have an LRRK2 gene test result
📍 Banner Sun Health Research Institute · Sun City, AZ · +39 more US sites · Get directions →
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.
- Depression
A Randomized Neuroimaging Trial of Psilocybin in Depression
Testing whether psilocybin changes brain activity in people with depression compared with placebo
📍 Sunnybrook Health Sciences Centre · Toronto, Ontario · Get directions →
The goal of this neuroimaging clinical trial is to test whether psilocybin produces significant immediate changes in functional brain activity in networks associated with mood regulation and depression compared to placebo in patients with depression. The trial aims to determine if psilocybin: 1.
- Multiple sclerosis (MS)
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Testing safety of a twice-yearly medicine for early relapsing MS
📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →
In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.
- Depression
Dopaminergic Therapy for Anhedonia - 2
Testing an 8-week treatment using L-DOPA for depression with low pleasure and high inflammation
📍 Emory University Hospital · Atlanta, GA · Get directions →
The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks.
- Anxiety
Self-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy
Testing whether self-controlled nitrous oxide during vasectomy lowers pain and anxiety
📍 Beth Israel Deaconess Medical Center · Boston, MA · Get directions →
This study is being done to see if nitrous oxide during vasectomy decreases pain and anxiety, and also assess whether patients have better satisfaction when they control their own level of nitrous oxide during the procedure. If we find that patients experience less pain or anxiety with nitrous oxide, it could be suggested that self-adjusted nitrous oxide (SANO) may be a useful tool for improving experience of care during vasectomy.
- Depression
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
Testing a medicine versus placebo for safety and effectiveness in adults with major depression
📍 Collaborative Neuroscience Network · Garden Grove, CA · Get directions →
This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder
- Depression
Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression
Testing how one-time exercise and ibuprofen affect bipolar depression symptoms
📍 Laureate Institute for Brain Research · Tulsa, OK · Get directions →
This is a 2x2, within-subjects, cross-over trial to test the anti-depressant effects of acute exercise in 20 participants with bipolar depression. Participants will complete four experimental sessions, two with an exercise challenge and two with a resting control condition in a counterbalanced order.
- Depression
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
Testing changes in depression symptoms and side effects from an oral medicine
📍 Harmonex /ID# 277517 · Dothan, AL · +32 more US sites · Get directions →
Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains.
- Depression
RCT of Psilocybin-assisted CBT for Depression
Testing psilocybin with cognitive-behavioral therapy for depression
📍 UCLA Semel Institute · Los Angeles, CA · Get directions →
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder. This study is a randomized, two-arm, fixed dose trial that will test the feasibility, acceptability, and participant and therapist adherence to PA-CBT.
- Depression
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Testing a drug called ACP-211 for adults with depression who did not improve with antidepressants
📍 University of Alabama at Birmingham · Birmingham, AL · +20 more US sites · Get directions →
The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression?
- Parkinson's disease
A Study of Buntanetap in Participants With PD
Testing the long-term safety of buntanetap in people with Parkinson’s
📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.
- Depression
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Comparing pramipexole and escitalopram for depression in people with HIV
📍 Alabama CRS · Birmingham, AL · +24 more US sites · Get directions →
A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes.
- Depression
Identifying and Treating Depression in the Orthopaedic Trauma Population
Testing how orthopedic trauma teams can screen for depression and treat it with medication
📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →
The goal of this trial is to pilot a way for orthopaedic surgeons to safely screen for depression and provide treatment for depression with medication. The main questions it aims to answer are: 1.
- DepressionAnxiety
iTBS+D-Cycloserine for Youth Suicide
Testing a treatment for depression and anxiety to reduce youth suicide risk
📍 University of Calgary · Calgary, Alberta · Get directions →
Background and Rationale: Suicide is the second leading cause of death in Canadian Emerging Adults (EAs; 18-24yrs). Current treatments for suicidal thoughts and behaviors are limited and novel treatments are required to save lives.
- Fatty liver disease (NASH/MASH)
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Testing drugs together or alone to lower liver fat in adults with MASH
📍 Arizona Liver Health · Chandler, AZ · +39 more US sites · Get directions →
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.
- Depression
Psilocybin rTMS for Treatment Resistant Depression
Testing whether psilocybin paired with a brain stimulation treatment is safe in people with
📍 Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 · Austin, TX · Get directions →
The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.
- Depression
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Testing whether DT-101 treats depression in adults compared with placebo
📍 Draig Clinical Site · Bentonville, AR · +22 more US sites · Get directions →
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo.
- Depression
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
Testing whether blocking inflammation with an IV medicine affects thinking speed in people with
📍 Massachusetts General Hospital · Boston, MA · Get directions →
This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.
- Multiple sclerosis (MS)
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Testing whether combining a walking medication with physical therapy improves mobility in people
📍 MGH Institute of Health Professions · Boston, MA · Get directions →
The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?
- DepressionAnxiety
Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
Studying how gut bacteria in pregnant people relates to depression and anxiety
📍 Sunnybrook Health Science Center · Toronto, Ontario · Get directions →
Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies.
- Anxiety
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
Testing whether sertraline works better than a placebo for anxiety in children with
📍 Alberta Children's Hospital - University of Calgary · Calgary, Alberta · Get directions →
There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs.
- Depression
Allopregnanolone (Zuranolone) in Post-stroke Depression
Testing whether a pill called zuranolone is safe and helps depression after a stroke
📍 Duke South Neurology Clinic 1L · Durham, NC · Get directions →
The goal of this Phase II clinical trial is to learn if the oral synthetic allopreganolone analog (zuranolone) is safe to take and is well tolerated by stroke survivors experiencing moderate to severe post-stroke depression and if it will help with the symptoms of depression. The main questions it will aim to answer are: * Is zuranolone safe to take by participants who have moderate to severe post-stroke depression?
- Parkinson's disease
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
Testing a carbidopa and levodopa extended-release capsule in people with Parkinson’s
📍 Barrow Neurological Institute · Phoenix, AZ · +26 more US sites · Get directions →
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
- DepressionAnxiety
Leveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City
Testing whether a phone-based program supports opioid recovery and mental health
📍 Washington University School of Medicine · St Louis, MO · Get directions →
The sequential trial compares recovery and mHealth engagement outcomes among Black participants who participated in the mHealth intervention uMAT-R or uMAT-R + enhanced community engagement. The mHealth intervention seeks to support people in various stages of recovery who are also seeking other forms of substance use treatment.
- Multiple sclerosis (MS)
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Testing a drug called BMS-986368 for muscle stiffness in multiple sclerosis
📍 Alabama Neurology Associates · Birmingham, AL · +14 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
- Depression
Stratified Pharmacological Approaches for Regulating Circuit-Level Effects
Testing how pramipexole affects depression symptoms and brain circuits
📍 Stanford University · Palo Alto, CA · Get directions →
This research study aims to understand how people with depression respond to the medication pramipexole and to determine whether clinical response differs depending on the function of specific circuits in the brain. The investigators hope to learn which circuits are involved in depression and how these circuits interact with pramipexole to affect mood, behavior, and cognition.
- Anxiety
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Testing whether adding ABBV-932 to antidepressants is safe and helps adults with generalized anxiety
📍 University of Alabama - Huntsville Regional Medical Campus /ID# 267818 · Huntsville, AL · +39 more US sites · Get directions →
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs.
- Multiple sclerosis (MS)
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Checking if two under-the-skin versions of ocrelizumab match in the body in people with multiple
📍 Profound Research, LLC · Carlsbad, CA · +8 more US sites · Get directions →
The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation.
- Fatty liver disease (NASH/MASH)
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
Testing whether daily soy milk affects liver disease in children with fatty liver
📍 Cincinnati Children's Hospital Medical Center · Cincinnati, OH · Get directions →
A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities.
- Multiple sclerosis (MS)
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
Testing whether corticosteroids change inflammation in acute MS lesions
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: Multiple sclerosis (MS) affects the brain, spinal cord, and optic nerves. MS lesions can appear on the MRI (magnetic resonance imaging) scans in many ways.
- Fatty liver disease (NASH/MASH)💵 May compensate
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Testing how the liver responds to glucose in fatty liver disease, and semaglutide’s effect
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.
- Fatty liver disease (NASH/MASH)
A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
Testing how safe and effective HU6 is for adults with MASH
📍 Arizona Liver Health - Chandler · Chandler, AZ · +30 more US sites · Get directions →
Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also asse
- Depression
Neutralizing Interleukin (IL)-6
Testing whether a shot that blocks IL-6 is safe in adults with depression
📍 Icahn School of Medicine at Mount Sinai · New York, NY · Get directions →
The proposed study aims to establish the feasibility and safety of subcutaneous tocilizumab, a monoclonal antibody (mAb) against interleukin (IL)-6 receptor, in adults with Major Depressive Disorder (MDD) and evidence of peripheral immune activation. IL-6 is a pro-inflammatory cytokine implicated in the pathophysiology of depression.
- Depression
Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)
Testing whether lemborexant helps persistent insomnia in adults with depression
📍 St. Michael's Hospital, Unity Health Toronto · Toronto, Ontario · Get directions →
The goal of this clinical trial is to learn if Lemborexant works to treat residual insomnia in adults with depression that is being treated. It will also learn about how practical, tolerable, and effective Lemborexant is.
- Depression
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin
Testing whether one or two doses of psilocybin help treatment-resistant depression and are well
📍 Toronto Western Hospital · Toronto, Ontario · Get directions →
The purpose of this study is to see if one or two doses of psilocybin is more effective in relieving depressive symptoms in patients with treatment-resistant depression (TRD). Researchers also want to know if a second dose of psilocybin is safe and well-tolerated.
- Depression
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
Comparing best step-by-step treatments for depression with anxiety
📍 University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience · Cincinnati, OH · Get directions →
Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.
- Multiple sclerosis (MS)
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Testing solriamfetol to treat tiredness from multiple sclerosis
📍 Johns Hopkins University · Baltimore, MD · Get directions →
Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness.
- Depression
Regulation of Affect and Physiology in Depression
Testing how feelings and body changes relate to depression
📍 University of Southern California · Los Angeles, CA · Get directions →
Although treatments for depression are effective for many people, not everyone responds to treatment. This lack of treatment response could be due, in part, to the presence of multiple underlying causes of people's depression.
- Fatty liver disease (NASH/MASH)💵 May compensate
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Testing how SGLT2 inhibitors work for fatty liver disease in obese teens
📍 Ann & Robert H Lurie Children's Hospital of Chicago · Chicago, IL · Get directions →
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- DepressionAnxiety
A New Intervention to Improve Function in Veterans With Anxiety and Depression
Testing a new treatment to improve daily functioning in veterans with anxiety and depression
📍 Durham VA Medical Center, Durham, NC · Durham, NC · Get directions →
Anxiety and depression symptoms occur at high rates in Veteran populations and can significantly impact function, compromising the ability to work and to successfully form and maintain valued relationships. Several other symptoms commonly occur with anxiety and depression, including poor sleep quality and chronic pain.
- Obesity / overweightFatty liver disease (NASH/MASH)💵 May compensate
Fibrosis Lessens After Metabolic Surgery
Testing whether metabolic surgery can reduce liver scarring in obesity
📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.
- Depression
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II
Testing propofol with therapy to improve depression-related sleep in older adults
📍 Washington University School of Medicine/Barnes-Jewish Hospital · St Louis, MO · Get directions →
The investigators hypothesize that brief behavioral therapy and targeted propofol infusion in depressed geriatric patients will augment subsequent slow wave sleep and improve clinical and cognitive outcomes. The team will recruit 70 participants for a double-blinded placebo controlled randomized controlled trial.
- Depression
Apimostinel + Automated Neurocognitive Training for Depression
Testing a new depression medicine plus brain-training exercises
📍 Western Psychiatric Institute and Clinic · Pittsburgh, PA · Get directions →
Apimostinel shows initial promise as a novel rapid-acting antidepressant medication with minimal side effects or safety concerns. Cognitive Training (CT) is a digital intervention that has shown promise in extending the durability of another similar drug (ketamine).
- Anxiety
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
Testing whether genetic-guided dosing of a daily anxiety medicine helps kids
📍 University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience · Cincinnati, OH · Get directions →
This double-blind, 12-week study will consist include132 anxious youth who are randomized (1:1) to standard or pharmacogenetically-guided escitalopram dosing. Block randomization (1:1) will be stratified by sex and metabolizer status.
- DepressionParkinson's disease
Imaging Depression in Parkinson's Disease
Studying brain changes linked to depression in people with Parkinson’s
📍 Yale University · New Haven, CT · Get directions →
The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.
- Showing the first 60 of 223. Add filters or a location to narrow down.